Abstract
This article outlines some of the complexities and challenges confronting researchers and the US Food and Drug Administration (FDA) in the area of evaluation of antimetastatic and other novel anticancer therapies. The scientific regulatory matrix utilized by the FDA is outlined. Subsequently, the complications encountered when designing and interpreting studies of antimetastatic drugs are described, and finally changes in the regulatory landscape both within the USA and internationally are considered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Friedman, M. Regulatory issues in the evaluation of antimetastatic and other novel anticancer therapies. Cancer Chemother Pharmacol 43 (Suppl 1), S100–S103 (1999). https://doi.org/10.1007/s002800051106
Issue Date:
DOI: https://doi.org/10.1007/s002800051106